Navigation Links
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Date:2/6/2008

ency (EMEA) for Cimzia(R) in the treatment of RA is ongoing, with filing planned in the first half of 2008.

In September 2007, Cimzia(R) was approved in Switzerland for the treatment of Crohn's disease and it was launched in January 2008.

About Rheumatoid Arthritis

RA is a progressive autoimmune disease that causes chronic inflammation of the joints. It is estimated that five million people suffer from RA globally, with 0.3 percent to 1 percent of the population in industrialized countries suffering from the disease. Women are three times more likely to be affected than men. Although it can affect people of all ages, the onset of RA usually occurs between the ages of 35-55.

Traditional treatments for RA include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs), with biological therapies a more recent addition.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on Euronext Brussels.

UCB Forward-Looking Statement

This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the development and commercialization of certolizumab pegol. Among the factors that could cause actual results to differ materially from those indicated by such forward- looking statements are: the results of research, development and clinical trial
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
2. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
(Date:12/19/2014)... 18, 2014 Today, TiFiber, ... pilot production facility and future company headquarters in ... innovative new materials that safely and effectively control ... because of its historic, strong support for manufacturing, ... attract leading edge, technology-based companies such as TiFiber. ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... could improve the life of the lithium batteries ... players, and mobile phones. Research to be published ... Nanomanufacturing - demonstrates that carbon nanotubes can prevent ... time. , Researchers at the Shenyang National Laboratory ...
... 10 Hologic, Inc.,(Nasdaq: HOLX ) today ... presenting at the Sun Trust Robinson Humphrey,s 37th ... Ritz-Carlton Hotel in,Buckhead, GA., Interested parties are ... of,Hologic,s investor presentation on Wednesday, April 16, 2008, ...
... are 14 prescription drugs that,exceeded $20 billion in sales in ... in four years. Prescription to OTC switches,were frequent in 2006 ... of the Rx to OTC Switch: Market Analysis and Product ... Rx to OTC are forecast to reach $5 billion in ...
Cached Biology Technology:Sweet nanotech batteries 2Hologic to Present at the Sun Trust Robinson Humphrey's 37th Annual Institutional Conference 2Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback 2
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... ahead of a deadly disease that has wiped out more ... continue to discover new frog species in Panama: Pristimantis ... adnus from Darien Province near the Colombian border. , ... world. Then they identified the cause: a fungal disease called ...
... Irvine scientists have created an eight-layer, early-stage retina from ... to be made from stem cells. It also ... retinas to treat eye disorders such as retinitis pigmentosa ... a complex structure consisting of many cell types," said ...
... Medicine have identified in mice a previously unknown protective ... clots and other blockages from the brain. The findings ... age-related cognitive decline, Alzheimer,s disease and recovery from stroke. ... May 27 issue of Nature by Jaime ...
Cached Biology News:2 new frog species discovered in Panama's fungal war zone 2UCI researchers create retina from human embryonic stem cells 2Researchers discover new mechanism for clearing blockages from smallest blood vessels 2
... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
Request Info...
... ExcelGel DNA Analysis Kit, 1. ... polymorphisms and high resolution DNA typing. ... set-up and clean-up. *Precast, plastic-backed gels ... handling convenience and detection sensitivity. ...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Biology Products: